CRNDE promoted HCC proliferation and sorafenib resistance through associations with the epigenetic regulator protein, p300, and transcription factor, YY1, and further regulation of chromatin relaxation to mediate EGFR expression and activity. This evidence concerns the gene YY1 and hepatocellular carcinoma.